Samsung Bioepis Announces Phase 3 Exploratory Analyses Results of AYBINTIO (Bevacizumab)

Goodwin
Contact

GoodwinSamsung Bioepis announced positive results yesterday from its exploratory analyses of the Phase 3 study of its biosimilar product, AYBINTIO (bevacizumab).  The study compared AYBINTIO’s efficacy to reference bevacizumab in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).  According to Vice President and Team Lead of Medical & Lifecycle Safety Seongwon Han, the results “reinforce equivalent clinical efficacy between AYBINTIO and reference bevacizumab.”

 The study enrolled 665 patients, 337 of whom received AYBINTIO and 328 of whom received reference bevacizumab with paclitaxel and Q3W carboplatin up to six cycles followed by AYBINTIO or reference bevacizumab maintenance monotherapy.  The primary endpoint was overall response rate (ORR) by 24 weeks of induction treatment.  The analysis of the current study showed the risk difference in best ORR by 11 and 17 weeks was 2.2%  (95% CI, –4.6% to 9.1%) and 2.4% (95% CI, –5.1% to 10.0%), respectively.  The mean of maximum percentage change in tumor burden by week 24 was -27.8% for AYBINTIO and -27.3% for reference bevacizumab.

Samsung Bioepsis will present the results of the AYBINTIO Phase 3 exploratory analyses in e-poster format during ESMO’s Science Weekend on Thursday, September 17, 2020.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.